Literature DB >> 18562097

Caffeine reverses antinociception by amitriptyline in wild type mice but not in those lacking adenosine A1 receptors.

Jana Sawynok1, Allison R Reid, Bertil B Fredholm.   

Abstract

Amitriptyline is used to treat neuropathic pain in humans. It produces antinociception in several animal models of pain, and this effect is blocked by methylxanthine adenosine receptor antagonists which implicates adenosine it its actions. Here, the antinociceptive effect of amitriptyline, and the ability of caffeine to reverse it, were examined using the formalin test (a model of persistent pain) in wild type mice and mice lacking the adenosine A(1) receptor (A1R). Amitriptyline produced dose-related suppression of flinching in wild type mice following both systemic and intraplantar drug administration; both of these effects were unaltered in A1R -/- mice. Following systemic administration, caffeine reversed the systemic effect of amitriptyline in wild type, but not A1R -/- mice; -/+ mice exhibited an intermediate effect. Intraplantar administration of caffeine also reversed the effect of intraplantar amitriptyline in A1R +/+, but not in -/- or +/- mice. These results indicate that adenosine A(1) receptors are not required in order for amitriptyline to cause antinociception in mice, but they are required to see caffeine reversal of this antinociceptive effect. When A1Rs are present, actions of amitriptyline may, however, partly depend on A1Rs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562097     DOI: 10.1016/j.neulet.2008.05.074

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  6 in total

1.  Antinociceptive, antiedematous, and antiallodynic activity of 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives in experimental models of pain.

Authors:  Anna Dziubina; Dominika Szkatuła; Joanna Gdula-Argasińska; Magdalena Kotańska; Barbara Filipek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-19       Impact factor: 3.000

2.  Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion.

Authors:  Cristiano R Jesse; Ethel A Wilhelm; Cristina W Nogueira
Journal:  Psychopharmacology (Berl)       Date:  2010-08-06       Impact factor: 4.530

3.  Influences of smoking and caffeine consumption on trigeminal pain processing.

Authors:  Dagny Holle; Anke Heber; Steffen Naegel; Hans-Christoph Diener; Zaza Katsarava; Mark Obermann
Journal:  J Headache Pain       Date:  2014-06-13       Impact factor: 7.277

4.  Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System.

Authors:  Eveline Dischkaln Stolz; Paola Fontoura da Costa; Liciane Fernandes Medeiros; Andressa Souza; Ana Maria Oliveira Battastini; Gilsane Lino von Poser; Carla Bonan; Iraci L S Torres; Stela Maris Kuze Rates
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-21       Impact factor: 2.629

Review 5.  Caffeine in the management of patients with headache.

Authors:  Richard B Lipton; Hans-Christoph Diener; Matthew S Robbins; Sandy Yacoub Garas; Ketu Patel
Journal:  J Headache Pain       Date:  2017-10-24       Impact factor: 7.277

Review 6.  Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain.

Authors:  Fabrizio Vincenzi; Silvia Pasquini; Pier Andrea Borea; Katia Varani
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.